Second Major Coronavirus Vaccine Trial Kicks Off In UK

The wait for a working COVID-19 vaccine continues. Though cures normally take a year to come out, researchers and scientists continue to race against time to come up with one. To date, all they can do is an experiment and do trials with hopes of providing a working cure. Experts over at the Imperial College London will join the fray with plans to start its second major human trials by next week.

The team will be led by Professor Robin Shattock. They have developed an RNA vaccine that is meant to help muscle cells by spiking the protein on the surface of the coronavirus. The said protein will be tasked to provoke an immune response that will, in turn, safeguard an individual against the dreaded COVID-19 strain. The vaccine is set to enter phase one. Phase two will involve human trials on 300 individuals on June 15, the Sun reported.

If successful, vaccine trials will raise the number of human trials to 6,000 people in October. Should these efforts render positive results, the Imperial College London hopes to start distributing the vaccine in the U.K. and across the globe by early next year. Over in Oxford University, human clinical trials are already underway to potentially develop a separate vaccine.

Imperial College is already thinking ahead, forming a new social enterprise called VacEquity Global Health (VGH) to help develop the vaccine. All royalties will be waived over in the United Kingdom while low-income countries will be charged at cost-cut prices.

"The social enterprise's mission is to rapidly develop vaccines to prevent SARS-CoV-2 (Covid-19) infection and distribute them as widely as possible in the UK and overseas, including to low- and middle-income countries," Imperial College said in a statement.

Coronavirus COVID-19 Laboratory Test, Cure, Vaccine Extracting genetic material of the virus in Belo Horizonte, Brazil. Pedro Vilela/Getty Images

Shattock revealed how they have been busy the past six months trying to fast-track a working vaccine. It appears their efforts have paid off and they are now ready to deal with the coronavirus through their clinical trials.

"These new enterprises are the most effective way for us to deliver Covid-19 vaccines quickly, cheaply and internationally, while preparing for future pandemics," he said.

The U.K. Vaccine Taskforce is working closely with Imperial College and VGH in hopes of finally releasing a working cure against the pandemic. Chairwoman of the U.K. Vaccine Taskforce Kate Bingham lauded the efforts, believing that the efforts of Imperial College and VGH would be a big boost in finally coming up with a potential vaccine.